May patients be subject to hit because of SARS-CoV-2? A prospective study answers the question.

Conducted in France and Switzerland by the Hospital of Lariboisière Paris and the University Hospital of Geneva, the study on hospitalized SARS-CoV-2-infected patients has just been published in Thrombosis & Haemostasis journal (December issue)..

In hospitalized SARS-CoV-2-infected patients, elevated prevalence of thromboembolic events (TE) has been reported with subsequent recommendations to reinforce prophylactic anticoagulation using low-molecularweight (LMWH) or unfractionated-heparin (UFH).

For each patient referred by the attending physician for HIT suspicion, Lariboisière and Geneva Hospitals performed tests among which the HIT ConfirmTM test developed by Emosis.

Finally, the study suggests that COVID-19 patients receiving LMWH do not appear to be especially susceptible to HIT. Prevalence of HIT-associated antibodies is comparable to other critical illness settings and those antibodies do not seem to be associated with increased risk of TE and death.

To read more, please click on following link Thieme E-Books & E-Journals - Thrombosis and Haemostasis / Issue (